NCT06034938View on ClinicalTrials.gov

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

May 1, 2026

Conditions
Hiv
Interventions
DRUG

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]

Switch previous therapy with DOR/TDF/3TC

Trial Locations (4)

Unknown

RECRUITING

CHU de Caen, Caen

RECRUITING

CHU Orléans, Orléans

RECRUITING

CHU Rouen, Rouen

RECRUITING

CH Tourcoing, Tourcoing

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Hospital, Caen

OTHER

NCT06034938 - DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) | Biotech Hunter | Biotech Hunter